Design of Selective and Soluble Inhibitors of Tumor Necrosis Factor-α Converting Enzyme (TACE)

Autor: Rabinowitz, M. H., Andrews, R. C., Becherer, J. D., Bickett, D. M., Bubacz, D. G., Conway, J. G., Cowan, D. J., Gaul, M., Glennon, K., Lambert, M. H., Leesnitzer, M. A., McDougald, D. L., Moss, M. L., Musso, D. L., Rizzolio, M. C.

Publikováno v: Journal of Medicinal Chemistry; November 2001, Vol. 44 Issue: 24 p4252-4267, 16p

N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.

Autor: Musso DL; GlaxoSmithKline Research and Development, Five Moore Drive, Research Triangle Park, NC 27709, USA. dm12907@glaxowellcome.com, Andersen MW, Andrews RC, Austin R, Beaudet EJ, Becherer JD, Bubacz DG, Bickett DM, Chan JH, Conway JG, Cowan DJ, Gaul MD, Glennon KC, Hedeen KM, Lambert MH, Leesnitzer MA, McDougald DL, Mitchell JL, Moss ML, Rabinowitz MH, Rizzolio MC, Schaller LT, Stanford JB, Tippin T, Warner JR, Whitesell LG, Wiethe RW

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2001 Aug 20; Vol. 11 (16), pp. 2147-51.